484 Results
Sort By:
Published on May 8, 2024
A team of researchers at the Montefiore Einstein Comprehensive Cancer Center (MECCC) have demonstrated that altering two of the four key proteins in chimeric antigen receptors (CARs) improved their ability to attack and shrink glioblastoma, pancreatic, and lung tumors in mouse models of these cancers. The new approach, reported in…
Published on May 8, 2024
Scientists at Scripps Research have discovered a technique for boosting T cells’ ability to recognize and kill solid tumor cells. By removing a sugar present on the exterior of solid tumor cancer cells, T cells can move closer to their target. Studies in mice showed that the enhanced proximity of…
Published on April 5, 2024
Obsidian Therapeutics this week closed an oversubscribed $160.5 million Series C financing to try and crack the immunotherapy for solid tumors problem. The financing was led by Wellington Management. Obsidian’s lead candidate, OBX-115, is a novel engineered tumor-derived autologous T cell immunotherapy (tumor-infiltrating lymphocyte [TIL] cell therapy) “armored with pharmacologically…
Published on April 3, 2024
Adaptimmune’s pivotal SPEARHEAD-1 trial has shown that the T cell receptor therapy afami-cel effectively targets metastatic synovial sarcoma and myxoid round cell liposarcoma, potentially opening the door for other solid tumors to be treated with T cell therapies. “Synovial sarcoma is a rare cancer with historically limited treatment options and…
Published on March 26, 2024
A single mutation in MUTYH, a gene known to cause colorectal cancer, may cause other solid tumors, according to a study of over 350,000 patient biopsy samples conducted by researchers at the Johns Hopkins Kimmel Cancer Center, the Johns Hopkins Bloomberg School of Public Health, and Foundation Medicine. Their findings…
Published on March 18, 2024
Researchers at the UNC Lineberger Comprehensive Cancer Center have identified an enzyme that saps the energy of T cells once they have infiltrated a solid tumor and prevents them from effectively combatting cancer. The team found that the metabolic enzyme, called Acetyl-CoA Carboxylase (ACC) is turned “on” in the tumor…
Published on February 21, 2024
The Food and Drug Administration (FDA) has granted accelerated approval to lifileucel (Amtagvi, Iovance Biotherapeutics), a tumor-derived autologous T cell immunotherapy, for adult patients with unresectable or metastatic melanoma. It is the first, and the only one-time, T cell therapy to receive FDA approval for a solid tumor cancer. The…
Published on December 18, 2023
By Michael Fehlings, PhD Sponsored content brought to you by Therapeutics for solid tumors remain in a nascent corner of cancer research despite representing 90 percent of all cancers in adults. Thirty years after the first Chimeric Antigen Receptor (CAR) was reported, CAR-T cell therapies have seen significant breakthroughs…
Published on December 1, 2023
AbbVie continues the ADC party and beefs up its anti-solid tumor portfolio with the acquisition of ImmunoGen for $10.1B. ImmuoGen’s flagship cancer therapy is Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), according to an announcement yesterday. This has been the year of the…
Published on October 12, 2023
Researchers at the University of California, Los Angeles (UCLA) have developed a new treatment method using a nanocapsule to deliver the enzyme lactate oxidase into solid tumors, improving anti-tumoral immune response and immune checkpoint inhibitor therapy efficacy.Reporting in Science Translational Medicine, scientists are targeting lactate—a chemical produced by cancer cells…
Published on August 2, 2023
Researchers at City of Hope have developed a new targeted chemotherapy that shows promise against all solid tumor types, in preclinical studies. The new drug candidate, AOH1996, targets proliferating cell nuclear antigen (PCNA) a protein once that to be “undruggable” with early research showing that the targeted chemotherapy appears to…
Published on July 26, 2023
Chimeric antigen receptor (CAR) T cell therapy has exhibited very promising results as a treatment for blood cancers such as leukemia and lymphoma. However, the immunotherapy’s ability to deliver similar results is solid tumors has been hampered by the tumor microenvironment which attacks the CAR T therapy. Now, researchers at…
Published on July 5, 2023
Researchers at the Massachusetts Institute of Technology (MIT) say they have used a vaccine that boosts CAR T therapy and it may be a method that can help this form of immunotherapy effectively treat solid tumors. The MIT researchers have found a way to overcome one of the obstacles to…
Published on March 16, 2023
Researchers at the Perelman School of Medicine at the University of Pennsylvania have developed a new and improved CAR T cell therapy approach for solid tumors by simultaneously knocking out two inflammatory regulators and boosting T cell expansion. CAR T cells are immune cells taken from an individual patient and genetically…
Published on March 2, 2023
Investigators at Children’s Hospital Los Angeles (CHLA) have developed a liquid biopsy for solid tumors that could help deliver a specific diagnosis when a tissue biopsy is not feasible. The test looks at cell-free (cf) DNA from plasma to detect genome-wide copy number alterations (CNAs) and gene fusions. The first…